Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-novel coronavirus antibody and preparation method and application thereof

A coronavirus, a new type of technology, applied in the field of anti-new coronavirus antibodies and its preparation, can solve the problems of limited auxiliary role in the prevention and control of group viruses, inability to achieve specific killing of pathogens, and high degree of dependence on the external environment. It is not easy to achieve Allergic reactions, wide range of protection, and the effect of less dosage

Active Publication Date: 2020-08-18
CHENGDU YUKANG BIOTECHNOLOGY CO LTD
View PDF3 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The chemical killing method is to kill viruses by using broad-spectrum chemical agents that kill bacteria and viruses, such as 84 disinfectant, medical alcohol, etc. Chemical agents generally have certain toxicity to the human body, so they are mostly used as environmental antivirus. However, it cannot be directly applied to the surface of sensitive organs of the human body, such as eyes, ears, mouth, nose, etc. Some chemical agents with strong chemical toxicity cannot even have excessive contact with human skin, so the protective effect on the human body is very limited; while the physical killing method requires high temperature Viruses are killed by physical means such as high pressure, ultraviolet rays, etc., but this method is highly dependent on the external environment, and it cannot be directly applied to the protection of the human body surface. Neither the chemical killing method nor the physical killing method can achieve pathogens Specific killing, large side effects, very limited auxiliary effect on the prevention and control of mass viruses

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-novel coronavirus antibody and preparation method and application thereof
  • Anti-novel coronavirus antibody and preparation method and application thereof
  • Anti-novel coronavirus antibody and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] The present invention specifically provides an anti-new coronavirus antibody, which is characterized in that the antibody is a high-titer specific antibody extracted from chicken egg yolk, and the chicken egg yolk is mainly obtained from eggs produced by immunized hens. Obtained, the immunized hen is a healthy hen injected with a new coronavirus vaccine.

[0029] Wherein, the novel coronavirus vaccine is mainly prepared from recombinantly expressed novel coronavirus (SARS-CoV-2) S antigen or virus-inactivated novel coronavirus (SARS-CoV-2) antigen.

[0030] Its specific preparation method comprises the following steps:

[0031] 1. Antibody preparation:

[0032] S1. Vaccine preparation:

[0033]Take the novel coronavirus (SARS-CoV-2) S antigen expressed recombinantly or the virus-inactivated novel coronavirus (SARS-CoV-2) antigen, and add the antigen into Freund's complete adjuvant in a ratio of 1:1 (initial immunization) or Freund's incomplete adjuvant (boosting immu...

Embodiment 2

[0056] This embodiment compares the yolk antibody production situation of two groups of different antigen immunization doses, and the preferred antigen immunization dose is specifically shown in the following table:

[0057] Table 1 The rise and fall of egg yolk antibody titers with different antigen immunization doses

[0058] immune dose 4 weeks after priming 5 weeks after priming 6 weeks after priming 8 weeks after priming 10 weeks after priming 5μg / feather 1:16000 1:80000 1:80000 1:80000 1:64000 10μg / feather NT 1:40000 1:40000 1:80000 1:32000

[0059] (NT: As the hens did not lay eggs after immunization, no detection was performed.)

[0060] It can be seen from the above table that the 5 μg / feather antigen dose group is preferred, and the yolk antibody titers produced in this dose group after 6, 8, and 10 weeks of primary vaccination are not lower than the 10 μg / feather antigen dose group.

Embodiment 3

[0062] In this embodiment, in order to verify the anti-new coronavirus yolk antibody neutralizing virus performance, the following tests were carried out:

[0063] take 10 5 ~10 7 TCID 50 The new coronavirus liquid per ml is mixed with the new coronavirus egg yolk antibody samples with a concentration of 1mg / ml, 2mg / ml, and 3mg / ml according to the volume ratio of 1:1, and then neutralized at 25-37°C for 1-2 hours. Add it to a 96-well plate containing cells, incubate in a carbon dioxide incubator at 33-35°C, and observe cell changes daily under a microscope.

[0064] Under the condition of 25-37°C, the new coronavirus yolk antibody with a concentration of 2mg / ml and 3mg / ml was mixed with the new coronavirus liquid of 105-107 TCID50 / ml, and the cells had no pathological changes. As a positive control, the novel coronavirus liquid can cause pathological changes in cells.

[0065] It can be seen from the test results that the anti-new coronavirus IgY prepared in the present in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Molecular weightaaaaaaaaaa
Molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention discloses an anti-novel coronavirus antibody. The antibody is a high-titer specific antibody extracted from chicken egg yolk, the chicken egg yolk is mainly obtained from eggs laid by immunized hens, and the immunized hens are healthy hens injected with novel coronavirus vaccines. The invention also discloses an adjuvant drug for preventing and controlling the novel coronavirus, which takes the antibody for resisting the novel coronavirus as a main component. The drug exerts the characteristics of the antibody for resisting the novel coronavirus, can be specifically combined withthe novel coronavirus of the oropharynx and the nasal cavity in a short time, is long in retention time, painless, non-irritant, good in safety performance and free of toxic and side effects, can beused for prevention and blocking of novel coronavirus infection and adjuvant therapy of early infection, and can be used for group virus prevention and control adjuvant medication.

Description

technical field [0001] The invention relates to the technical field of biological antibody immunization, and specifically refers to an anti-new coronavirus antibody and its preparation method and application. Background technique [0002] Coronaviruses belong to the order Nidovirales, Coronaviridae, and the genus Coronavirus. They are important pathogens of many domestic animals and pets, including human diseases, and cause a variety of acute and chronic diseases. The Ninth International Committee on Virological Classification reported that Coronaviridae was divided into three genera namely α, β and γ genera. The novel coronavirus belongs to the Sarbecovirus subgenus of betacoronaviruses. [0003] Novel coronavirus pneumonia is a new infectious disease, and the population has no immunity and is generally susceptible. Novel coronavirus-infected pneumonia can occur in people with low immune function and normal immune function, and it has a certain relationship with the amoun...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/10C07K16/02C07K1/36C07K1/34C07K1/30A61K39/42A61K9/08A61P31/14
CPCA61K9/08A61K2039/505A61K2039/542A61K2039/543A61K2039/544A61P31/14C07K16/02C07K16/10C07K2317/11C07K2317/76
Inventor 林小军杨鹏辉武婕廖明王欢朱玲雷雨胡方炎叶向阳叶琳
Owner CHENGDU YUKANG BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com